ORIC
ORIC Pharmaceuticals, Inc.
Biotechnology
Market Cap$912M
5Y Perf.-69.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ORIC vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$652M
5Y Perf.-69.4%
ORIC vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ORIC | ARVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $912M | $652M |
| Revenue (TTM) | $0.00 | $263M |
| Net Income (TTM) | $-135M | $-81M |
| Gross Margin | — | 99.5% |
| Operating Margin | — | -44.0% |
| Total Debt | $12M | $9M |
| Cash & Equiv. | $46M | $143M |
ORIC vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ORIC
ARVN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| ORIC Pharmaceutical… (ORIC) | 100 | 30.4 | -69.6% |
| Arvinas, Inc. (ARVN) | 100 | 30.6 | -69.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORIC vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ORIC and ARVN are tied at the top with 2 categories each — the right choice depends on your priorities. Arvinas, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ORIC
ORIC Pharmaceuticals, Inc.
The Income Pick
ORIC has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- beta 1.12
- Lower volatility, beta 1.12, Low D/E 3.0%, current ratio 14.13x
- Beta 1.12, current ratio 14.13x
Best for: income & stability and sleep-well-at-night
ARVN
Arvinas, Inc.
The Growth Play
ARVN is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -0.3%, EPS growth 53.8%, 3Y rev CAGR 26.0%
- -36.5% 10Y total return vs ORIC's -65.8%
- -0.3% revenue growth vs ORIC's -1.8%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARVN | -0.3% revenue growth vs ORIC's -1.8% |
| Stability / Safety | ORIC | Beta 1.12 vs ARVN's 1.15 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ORIC | +87.4% vs ARVN's +52.8% |
| Efficiency (ROA) | ARVN | -9.3% ROA vs ORIC's -33.3%, ROIC -22.4% vs -39.9% |
ORIC vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ORIC vs ARVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLORICLAGGINGARVN
ARVNArvinas, Inc.
2leads
ORICORIC Pharmaceuticals,…
2leads
6 Total Categories
CATEGORYLEADERvs ARVNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ORIC1/1
Valuation MetricsMultiples, price ratios, and targets
ARVN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARVN8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ORIC5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ORIC leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ARVN and ORIC operate at a comparable scale, with $263M and $0 in trailing revenue.
| Metric | ORICORIC Pharmaceutic… | ARVNArvinas, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $263M |
| EBITDAEarnings before interest/tax | -$149M | -$111M |
| Net IncomeAfter-tax profit | -$135M | -$81M |
| Free Cash FlowCash after capex | -$111M | -$276M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% |
| Operating MarginEBIT ÷ Revenue | — | -44.0% |
| Net MarginNet income ÷ Revenue | — | -30.8% |
| FCF MarginFCF ÷ Revenue | — | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.0% | -65.1% |
ORIC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ARVN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ORICORIC Pharmaceutic… | ARVNArvinas, Inc. |
|---|---|---|
| Market CapShares × price | $912M | $652M |
| Enterprise ValueMkt cap + debt − cash | $878M | $517M |
| Trailing P/EPrice ÷ TTM EPS | -5.99x | -7.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.48x |
| Price / BookPrice ÷ Book value/share | 2.01x | 1.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
ARVN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ARVN leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
ARVN delivers a -14.3% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-35 for ORIC. ARVN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ORIC's 0.03x. On the Piotroski fundamental quality scale (0–9), ARVN scores 4/9 vs ORIC's 3/9, reflecting mixed financial health.
| Metric | ORICORIC Pharmaceutic… | ARVNArvinas, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -35.3% | -14.3% |
| ROA (TTM)Return on assets | -33.3% | -9.3% |
| ROICReturn on invested capital | -39.9% | -22.4% |
| ROCEReturn on capital employed | -44.7% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.02x |
| Net DebtTotal debt minus cash | -$34M | -$134M |
| Cash & Equiv.Liquid assets | $46M | $143M |
| Total DebtShort + long-term debt | $12M | $9M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ARVN leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ORIC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ORIC five years ago would be worth $3,689 today (with dividends reinvested), compared to $1,601 for ARVN. Over the past 12 months, ORIC leads with a +87.4% total return vs ARVN's +52.8%. The 3-year compound annual growth rate (CAGR) favors ORIC at 19.1% vs ARVN's -25.5% — a key indicator of consistent wealth creation.
| Metric | ORICORIC Pharmaceutic… | ARVNArvinas, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +7.8% | -11.2% |
| 1-Year ReturnPast 12 months | +87.4% | +52.8% |
| 3-Year ReturnCumulative with dividends | +68.8% | -58.7% |
| 5-Year ReturnCumulative with dividends | -63.1% | -84.0% |
| 10-Year ReturnCumulative with dividends | -65.8% | -36.5% |
| CAGR (3Y)Annualised 3-year return | +19.1% | -25.5% |
ORIC leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ORIC and ARVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ORIC is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than ARVN's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARVN currently trades 70.2% from its 52-week high vs ORIC's 59.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ORICORIC Pharmaceutic… | ARVNArvinas, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 1.15x |
| 52-Week HighHighest price in past year | $14.93 | $14.51 |
| 52-Week LowLowest price in past year | $4.52 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +59.0% | +70.2% |
| RSI (14)Momentum oscillator 0–100 | 39.7 | 42.6 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 808K |
Evenly matched — ORIC and ARVN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ORIC as "Buy" and ARVN as "Buy". Consensus price targets imply 146.9% upside for ORIC (target: $22) vs 27.6% for ARVN (target: $13).
| Metric | ORICORIC Pharmaceutic… | ARVNArvinas, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.75 | $13.00 |
| # AnalystsCovering analysts | 10 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
ORIC leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ARVN leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallORIC Pharmaceuticals, Inc. (ORIC)Leads 2 of 6 categories
Loading custom metrics...
ORIC vs ARVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ORIC or ARVN a better buy right now?
Analysts rate ORIC Pharmaceuticals, Inc.
(ORIC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ORIC or ARVN?
Over the past 5 years, ORIC Pharmaceuticals, Inc.
(ORIC) delivered a total return of -63. 1%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: ARVN returned -36. 5% versus ORIC's -65. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ORIC or ARVN?
By beta (market sensitivity over 5 years), ORIC Pharmaceuticals, Inc.
(ORIC) is the lower-risk stock at 1. 12β versus Arvinas, Inc. 's 1. 15β — meaning ARVN is approximately 3% more volatile than ORIC relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 3% for ORIC Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ORIC or ARVN?
On earnings-per-share growth, the picture is similar: Arvinas, Inc.
grew EPS 53. 8% year-over-year, compared to 19. 7% for ORIC Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ORIC or ARVN?
ORIC Pharmaceuticals, Inc.
(ORIC) is the more profitable company, earning 0. 0% net margin versus -30. 8% for Arvinas, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ORIC leads at 0. 0% versus -43. 8% for ARVN. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ORIC or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ORIC or ARVN better for a retirement portfolio?
For long-horizon retirement investors, ORIC Pharmaceuticals, Inc.
(ORIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Both have compounded well over 10 years (ORIC: -65. 8%, ARVN: -36. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ORIC and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.